Cardiovascular disease - DiabetesontheNet

Defining the role of lipid-lowering therapy in diabetes

Cardiovascular event reduction in high-risk patients

Do guidelines impact upon clinical results?

OGTT is needed for appropriate classification of glucose regulation in patients with CAD

Glycaemic durability of rosiglitazone, metformin or glibenclamide monotherapy

Intensive lipid lowering is beneficial. PROVE IT-TIMI!

Quantifying and addressing the cardiovascular risks of diabetes in South Asian populations

Moving forward with glitazones?

Using carotid artery intimal thickness to investigate the cardiovascular risk of pioglitazone versus glimepiride

Cardiovascular disease risk modification in abdominally obese people with type 2 diabetes

The endocannabinoid system: Its intervention and subsequent effects on cardiometabolic risk

Optimising the care of patients with type 2 diabetes and cardiovascular disease: Translating evidence-based medicine into practice

The significance of microalbuminuria in clinical practice

Managing CV risk in type 2 diabetes: Towards best practice (Part 3: Antihypertensive agents)

A cardiovascular risk algorithm for people not under current management

Persistent long-term increased risk for stroke in people with diabetes mellitus

At what age do people with diabetes become susceptible to developing cardiovascular disease?

Hyperglycaemia and hypertension increase risk of developing complications in people with type 2 diabetes